Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
300759.SZ Stock Summary
In the News
300759.SZ Financial details
Company Rating
Strong Buy
Market Cap
35.7B
Income
1.55B
Revenue
11.42B
Book val./share
6.92
Cash/share
1.73
Dividend
0.3
Dividend %
1.15%
Employees
19.48K
Optionable
No
Shortable
Yes
Earnings
28 Mar 2024
P/E
19.85
Forward P/E
14.91
PEG
-16.35
P/S
3.64
P/B
2.59
P/C
11.81
P/FCF
-56.89
Quick Ratio
1.54
Current Ratio
1.94
Debt / Equity
0.52
LT Debt / Equity
0.42
-
-
EPS (TTM)
1.23
EPS next Y
1.37
EPS next Q
-
EPS this Y
-17.14%
EPS next Y
11.61%
EPS next 5Y
-
EPS last 5Y
25.01%
Revenue last 5Y
28.69%
Revenue Q/Q
0.14%
EPS Q/Q
-43.24%
-
-
-
-
SMA20
-
SMA50
-18.52%
SMA100
-26.67%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
14%
ROC
0.1%
Gross Margin
36%
Oper. Margin
16%
Profit Margin
14%
Payout
26%
Shs Outstand
1.61B
Shs Float
837.75M
-
-
-
-
Target Price
-
52W Range
18.5-40.426666
52W High
-48.93%
52W Low
+13.5%
RSI
35
Rel Volume
0.84
Avg Volume
29.83M
Volume
25.19M
Perf Week
-10.55%
Perf Month
-1.3%
Perf Quarter
-
Perf Half Y
-29.5%
-
-
-
-
Beta
0.623
-
-
Volatility
0.9%, 1.12%
Prev Close
1.14%
Price
20.43
Change
-0.97%
300759.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.28 | 3.79 | 4.31 | 6.14 | 8.67 | |
Net income per share | 0.38 | 0.55 | 0.99 | 1.37 | 1.16 | |
Operating cash flow per share | 0.83 | 0.95 | 1.39 | 1.7 | 1.81 | |
Free cash flow per share | 0.11 | 0.19 | 0.28 | -0.03 | -0.68 | |
Cash per share | 0.36 | 4.69 | 3.24 | 4.2 | 1.89 | |
Book value per share | 2.63 | 7.84 | 7.46 | 8.35 | 8.91 | |
Tangible book value per share | 2.05 | 7.28 | 6.05 | 6.19 | 6.21 | |
Share holders equity per share | 2.63 | 7.84 | 7.46 | 8.35 | 8.91 | |
Interest debt per share | 1.68 | 1.13 | 0.9 | 4.42 | 5.31 | |
Market cap | 4.34B | 22.7B | 63.66B | 76.18B | 53.68B | |
Enterprise value | 5.44B | 19.28B | 61.77B | 77.92B | 58.3B | |
P/E ratio | 12.8 | 41.49 | 54.3 | 45.86 | 39.05 | |
Price to sales ratio | 1.49 | 6.04 | 12.4 | 10.23 | 5.23 | |
POCF ratio | 5.89 | 24.19 | 38.62 | 37.02 | 25.05 | |
PFCF ratio | 45.1 | 123.41 | 191.31 | -2.19K | -66.51 | |
P/B Ratio | 1.86 | 2.92 | 7.18 | 7.52 | 5.09 | |
PTB ratio | 1.86 | 2.92 | 7.18 | 7.52 | 5.09 | |
EV to sales | 1.87 | 5.13 | 12.03 | 10.47 | 5.68 | |
Enterprise value over EBITDA | 7.76 | 18.82 | 37.9 | 30 | 22.3 | |
EV to operating cash flow | 7.37 | 20.54 | 37.47 | 37.86 | 27.21 | |
EV to free cash flow | 56.47 | 104.81 | 185.63 | -2.24K | -72.24 | |
Earnings yield | 0.08 | 0.02 | 0.02 | 0.02 | 0.03 | |
Free cash flow yield | 0.02 | 0.01 | 0.01 | 0 | -0.02 | |
Debt to equity | 0.61 | 0.13 | 0.12 | 0.52 | 0.58 | |
Debt to assets | 0.31 | 0.1 | 0.09 | 0.29 | 0.3 | |
Net debt to EBITDA | 1.56 | -3.34 | -1.16 | 0.67 | 1.77 | |
Current ratio | 1.02 | 4.68 | 2.8 | 2.9 | 1.67 | |
Interest coverage | 5.31 | 7.66 | 55.5 | 23.04 | 10.1 | |
Income quality | 2.17 | 1.77 | 1.44 | 1.27 | 1.58 | |
Dividend Yield | 0.02 | 0.01 | 0 | 0 | 0.01 | |
Payout ratio | 0.22 | 0.26 | 0.12 | 0.17 | 0.29 | |
Sales general and administrative to revenue | 0.04 | 0.06 | 0.06 | 0.03 | 0.07 | |
Research and developement to revenue | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 | |
Intangibles to total assets | 0.11 | 0.06 | 0.15 | 0.15 | 0.17 | |
Capex to operating cash flow | -0.87 | -0.8 | -0.8 | -1.02 | -1.38 | |
Capex to revenue | -0.22 | -0.2 | -0.26 | -0.28 | -0.29 | |
Capex to depreciation | -3.03 | -2.38 | -3.51 | -4.2 | -4.24 | |
Stock based compensation to revenue | 0 | 0 | 0.01 | 0.01 | 0.02 | |
Graham number | 4.76 | 9.87 | 12.86 | 16.04 | 15.25 | |
ROIC | 0.08 | 0.06 | 0.11 | 0.1 | 0.08 | |
Return on tangible assets | 0.08 | 0.06 | 0.12 | 0.11 | 0.08 | |
Graham Net | -1.53 | 3.43 | 1.65 | -1.22 | -4.34 | |
Working capital | 24.85M | 4.67B | 3.56B | 5.66B | 2.62B | |
Tangible asset value | 1.81B | 7.21B | 7.2B | 7.51B | 7.35B | |
Net current asset value | -1B | 3.85B | 2.57B | 549.68M | -3.12B | |
Invested capital | 0.61 | 0.13 | 0.12 | 0.52 | 0.58 | |
Average receivables | 661.85M | 883.46M | 1.15B | 1.41B | 1.95B | |
Average payables | 99.93M | 113.1M | 154.74M | 253.52M | 360.94M | |
Average inventory | 106.86M | 138.93M | 219.51M | 480.83M | 860.75M | |
Days sales outstanding | 92.02 | 100.43 | 89.83 | 76.73 | 82.92 | |
Days payables outstanding | 20.12 | 17.77 | 21.77 | 24.17 | 22.83 | |
Days of inventory on hand | 22.39 | 23.71 | 32.02 | 52.09 | 58.5 | |
Receivables turnover | 3.97 | 3.63 | 4.06 | 4.76 | 4.4 | |
Payables turnover | 18.14 | 20.54 | 16.76 | 15.1 | 15.99 | |
Inventory turnover | 16.3 | 15.39 | 11.4 | 7.01 | 6.24 | |
ROE | 0.15 | 0.07 | 0.13 | 0.16 | 0.13 | |
Capex per share | -0.72 | -0.76 | -1.11 | -1.73 | -2.49 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.5 | 2.42 | 2.31 | 2.47 | 1.7 | |
Net income per share | 0.47 | 0.35 | 0.3 | 0.37 | 0.21 | |
Operating cash flow per share | 0.47 | 0.35 | 0.3 | 0.64 | 0.44 | |
Free cash flow per share | -0.64 | -0.28 | -0.37 | 0.03 | 0.01 | |
Cash per share | 3.46 | 1.89 | 2.16 | 2.67 | 1.73 | |
Book value per share | 13.15 | 8.91 | 9.3 | 9.77 | 6.92 | |
Tangible book value per share | 9.17 | 6.21 | 6.57 | 7.36 | 5.33 | |
Share holders equity per share | 13.15 | 8.91 | 9.3 | 9.77 | 6.92 | |
Interest debt per share | 7.27 | 5.2 | 5.26 | 5.21 | 3.62 | |
Market cap | 28.5B | 53.68B | 38.53B | 30.12B | 53.52B | |
Enterprise value | 32.16B | 58.3B | 42.63B | 33.71B | 57.65B | |
P/E ratio | 18.97 | 32.45 | 27.66 | 17.2 | 37.91 | |
Price to sales ratio | 10.3 | 18.75 | 14.15 | 10.33 | 18.33 | |
POCF ratio | 75.86 | 129.82 | 110.64 | 40.15 | 71.44 | |
PFCF ratio | -55.96 | -159.19 | -88.26 | 883.13 | 5.65K | |
P/B Ratio | 2.74 | 5.09 | 3.51 | 2.61 | 4.5 | |
PTB ratio | 2.74 | 5.09 | 3.51 | 2.61 | 4.5 | |
EV to sales | 11.62 | 20.36 | 15.65 | 11.56 | 19.74 | |
Enterprise value over EBITDA | 79.56 | 89.66 | 94.93 | 59.34 | 136.91 | |
EV to operating cash flow | 85.62 | 140.99 | 122.41 | 44.94 | 76.95 | |
EV to free cash flow | -63.16 | -172.89 | -97.64 | 988.43 | 6.09K | |
Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | -0.02 | -0.01 | -0.01 | 0 | 0 | |
Debt to equity | 0.55 | 0.58 | 0.56 | 0.53 | 0.52 | |
Debt to assets | 0.29 | 0.3 | 0.29 | 0.27 | 0.28 | |
Net debt to EBITDA | 9.06 | 7.1 | 9.13 | 6.32 | 9.81 | |
Current ratio | 1.82 | 1.67 | 1.67 | 1.84 | 1.94 | |
Interest coverage | 8.62 | 10.92 | 9.22 | 11.42 | 9.2 | |
Income quality | 1 | 1 | 1 | 1.71 | 2.12 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0.01 | |
Payout ratio | 0.17 | 0.03 | 0.04 | 0.03 | 1.04 | |
Sales general and administrative to revenue | 0.27 | -0.1 | 0.15 | -0.01 | 0.28 | |
Research and developement to revenue | 0.03 | 0.04 | 0.03 | 0.04 | 0.04 | |
Intangibles to total assets | 0.17 | 0.17 | 0.17 | 0.16 | 0.16 | |
Capex to operating cash flow | -2.36 | -1.82 | -2.25 | -0.95 | -0.99 | |
Capex to revenue | -0.32 | -0.26 | -0.29 | -0.25 | -0.25 | |
Capex to depreciation | 2.79 | -1.09 | -3.26 | -2.97 | 1.68 | |
Stock based compensation to revenue | 0.02 | 0.03 | 0 | 0.04 | 0.01 | |
Graham number | 11.85 | 8.37 | 7.86 | 9.03 | 5.65 | |
ROIC | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Return on tangible assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Graham Net | -5.27 | -4.34 | -4.01 | -3.74 | -2.45 | |
Working capital | 3.01B | 2.62B | 2.62B | 3.39B | 3.51B | |
Tangible asset value | 7.26B | 7.35B | 7.76B | 8.69B | 9.18B | |
Net current asset value | -2.51B | -3.12B | -3.21B | -2.65B | -2.53B | |
Invested capital | 0.55 | 0.58 | 0.56 | 0.53 | 0.52 | |
Average receivables | 2.19B | 2.33B | 2.47B | 2.64B | 2.71B | |
Average payables | 465.74M | 435.72M | 417.51M | 422.58M | 408.72M | |
Average inventory | 970.79M | 1.03B | 1.06B | 1.06B | 1.02B | |
Days sales outstanding | 75.74 | 73.3 | 86.22 | 82.48 | 84.41 | |
Days payables outstanding | 24.77 | 20.36 | 22.06 | 20.35 | 19.08 | |
Days of inventory on hand | 54.21 | 52.18 | 55.19 | 50.78 | 47.35 | |
Receivables turnover | 1.19 | 1.23 | 1.04 | 1.09 | 1.07 | |
Payables turnover | 3.63 | 4.42 | 4.08 | 4.42 | 4.72 | |
Inventory turnover | 1.66 | 1.72 | 1.63 | 1.77 | 1.9 | |
ROE | 0.04 | 0.04 | 0.03 | 0.04 | 0.03 | |
Capex per share | -1.12 | -0.63 | -0.67 | -0.61 | -0.43 |
300759.SZ Frequently Asked Questions
What is Pharmaron Beijing Co., Ltd. stock symbol ?
Pharmaron Beijing Co., Ltd. is a CN stock and trading under the symbol 300759.SZ
What is Pharmaron Beijing Co., Ltd. stock quote today ?
Pharmaron Beijing Co., Ltd. stock price is $20.43 today.
Is Pharmaron Beijing Co., Ltd. stock public?
Yes, Pharmaron Beijing Co., Ltd. is a publicly traded company.